v3.26.1
Collaborative, Licensing and Other Arrangements - Schedule of Recognized Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Other Revenue    
Other Revenue $ 1,513,438 $ 1,117,279
Other Revenue    
Other Revenue    
Other Revenue 26,109 8,749
Other Revenue | Novartis    
Other Revenue    
Other Revenue 26,109 8,749
Amgen royalty revenue | Novartis    
Other Revenue    
Other Revenue 18,297 5,519
Novartis broad markets revenue | Novartis    
Other Revenue    
Other Revenue 5,263 3,522
Other | Novartis    
Other Revenue    
Other Revenue $ 2,549 $ (292)